Q2 2021 Results - Reimagining Medicine
NEW INDICATIONS
Participants
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Novartis submission schedule
New Molecular Entities: Lead and supplementary indications
LEAD INDICATIONS
2021
177Lu-PSMA-617
AAA617
mCRPC 3L
asciminib
ABL001
CML 3L
tislelizumab
VDT482
2L esophageal cancer
2022
Lead ligelizumab
QGE031
2023
Lead iptacopan
Lead
CSU
Lead sabatolimab¹
Lead
MBG453
Lead
HR-MDS
tislelizumab
LCM
tislelizumab
LCM
VDT482
VDT482
NSCLC
1L Nasopharyngeal Carcinoma
LNP023
PNH
2024
SAF312
COSP
Lead
UNR844
Presbyopia
Lead
References
Innovation: Clinical trials
177 Lu-NeoB
AAA603
Multiple Solid Tumors
177 Lu-PSMA-R2
AAA602
Prostate cancer
branaplam
LMI070
Huntington's disease
CEE321
Atopic Dermatitis
cipargamin
KAE609
Malaria severe
CPK850
≥2025
Lead ganaplacide
KAF156
Malaria uncomplicated
Lead iscalimab
CFZ533
Knee osteoarthritis
Lead MIJ821
Depression
Lead
Lead NIS793
Lead
Solid tumors
Renal Tx
Lead ianalumab
Lead
OAV201
Lead
VAY736
AVXS-201
Sjögren's syndrome
Rett syndrome
Lead icenticaftor
QBW251
COPD
Lead
pelacarsen
Lead
TQJ230
CVRR-Lp(a)
Lead LNA043
Lead
remibrutinib
LOU064
CSU
Lead LXE408
Lead spartalizumab
Lead
RP
Visceral leishmaniasis
PDR001
Metastatic melanoma (combo)
CSJ117
Lead LXH254
Lead
TNO155
Lead
Asthma
Solid tumors (combo)
Solid tumors
gevokizumab
VPM087
Lead mavoglurant
Lead
tropifexor&licogliflozin Lead
AFQ056
1st line CRC / 1st line RCC
Cocaine use disorder
LJN452
NASH (combos)
LCM ligelizumab
QGE031
Food allergy
177Lu-PSMA-617
AAA617
Pre-taxane
iptacopan
LNP023
C3G
LCM tislelizumab
LCM
177Lu-PSMA-617
LCM
VDT482
1L ESCC
LCM tislelizumab
VDT482
AAA617
MHSPC
asciminib
ABL001
CML 1L
LCM iptacopan
LNP023
iMN
LCM
LCM sabatolimab
LCM cipargamin
LCM iscalimab
MBG453
KAE609
Localized ESCC
Unfit AML
Malaria uncomplicated
iptacopan
LCM tislelizumab
LCM tislelizumab
LCM
ianalumab
LNP023
IgAN
tislelizumab
VDT482
VDT482
VDT482
VAY736
1L Hepatocellular Carcinoma
1L Small Cell Lung Cancer
АІН
CFZ533
Liver Tx
LCM iscalimab
CFZ533
Sjögren's syndrome
LCM ligelizumab
QGE031
LCM
CINDU
LCM remibrutinib
LCM
LOU064
Sjögren's syndrome
LCM
tislelizumab
LCM
iptacopan
LCM
VDT482
1L Gastric Cancer
1L Bladder Urothelial Cell Carcinoma
LNP023
aHUS
1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials.
53 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation